Kenneth Griffin Reports 5.3% Passive Stake In Terns Pharmaceuticals As Of July 10
$TERN
Biotechnology: Pharmaceutical Preparations
Health Care
- SEC Filing
- SEC Filing
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/31/2024 | $82.00 | Outperform | Oppenheimer |
| 6/22/2023 | $16.00 | Buy | Mizuho |
| 6/7/2023 | $18.00 | Buy | Jefferies |
| 5/31/2023 | $23.00 | Buy | ROTH MKM |
| 5/8/2023 | $18.00 | Outperform | BMO Capital Markets |
| 2/14/2023 | $17.00 | Mkt Outperform | JMP Securities |
| 2/7/2023 | $19.00 | Buy | UBS |
| 9/12/2022 | $6.00 | Neutral | H.C. Wainwright |
SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
8-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
S-8 - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
10-Q - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc., to the Company's Board of Directors, effective immediately. In conjunction with Ms. Turner's appointment, Ann E. Taylor, M.D., is stepping down from the Board of Directors following more than three years of service. "It is my pleasure to welcome Heather to the Terns Board, and I am confide
Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for obesity expected in September 2024 Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL) in chronic myeloid leukemia (CML) expected in December 2024 Cash, cash equivalents and marketable securities of $225 million, expected to provide runway into 2026 FOSTER CITY, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today reported financial res
FOSTER CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Elona Kogan, Esq., as chief legal officer, effective immediately. Ms. Kogan brings a wealth of industry experience and has successfully guided several biotechnology companies through transformational growth and transactions. "Elona's proven leadership and deep industry knowledge make her an ideal addition to the Terns team," said Amy Burroughs, chief executive officer of
FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc., to the Company's Board of Directors, effective immediately. In conjunction with Ms. Turner's appointment, Ann E. Taylor, M.D., is stepping down from the Board of Directors following more than three years of service. "It is my pleasure to welcome Heather to the Terns Board, and I am confide
Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL tyrosine kinase inhibitor) in chronic myeloid leukemia (CML) expected in early December 2024 Plans to initiate Phase 2 clinical trial for TERN-601 in obesity in early 2Q25 with initial 12-week data expected in 2H25 Cash, cash equivalents and marketable securities of $372.8 million, including $172.7 million equity raise in September, expected to provide runway into 2028 FOSTER CITY, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecu
FOSTER CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in November. UBS Global Healthcare ConferenceFormat: Fireside Chat Date and Time: Wednesday, November 13, 2024 at 8:45 a.m. PTLocation: Terranea Resort, Rancho Palos Verdes Jefferies London Healthcare Conference Format: Fireside Chat Date and Time: Tuesday, November 19, 2024 at 5
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
3 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo adjusted) Well-tolerated with no treatment-related dose interruptions, reductions, or discontinuations even with rapid dose titration Distinct drug properties support potential to be a leading GLP-1R agonist Plans to initiate Phase 2 clinical trial in 2025 Company to host conference call today at 8:00 am ET FOSTER CITY, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, today announced positive top-line data from
TERN-501 demonstrated dose dependent MRI-PDFF reductions at Week 12 as a once-daily, low dose, and combinable oral therapy TERN-501 (6mg) showed statistically significant mean relative liver fat content reduction of 45% as assessed by MRI-PDFF with 64% of patients achieving >30% PDFF reduction All TERN-501 doses were well-tolerated with no gastrointestinal and no cardiovascular safety signals Company to host conference call and webcast at 4:30 pm ET today FOSTER CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidate
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
Oppenheimer initiated coverage of Terns Pharmaceuticals with a rating of Outperform and set a new price target of $82.00
Mizuho initiated coverage of Terns Pharmaceuticals with a rating of Buy and set a new price target of $16.00
Jefferies initiated coverage of Terns Pharmaceuticals with a rating of Buy and set a new price target of $18.00
- SEC Filing
GLP-1 market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) faced a significant selloff on Thursday, as new weight-loss drugs from rival pharmaceutical companies began threatening the dominance of their flagship products, Zepbound and Wegovy. Shares of Eli Lilly plummeted by 6.3%, marking their worst daily performance since March 2021. In the last two sessions, they have dropped by over 10%, registering the worst two-day downside since March 2020. Similarly, shares of Dutch pharmaceutical giant Novo Nordisk A/S fell 4%. Chart: Eli Lilly’s Worst Session In Over Three Years Image: Benzinga Pro Weight-Loss Market Sees New Entrants “This week is a pr
Shares of Conagra Brands, Inc. (NYSE:CAG) fell during Thursday's session after the company reported worse-than-expected fourth-quarter sales results and issued FY25 adjusted EPS guidance below estimates. The company reported adjusted earnings per share of 61 cents, beating the analyst consensus estimate of 57 cents. Quarterly revenues of $2.905 billion missed the street view of $2.930 billion, according to data from Benzinga Pro. Conagra Brands shares declined 3.9% to $27.70 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Kazia Therapeutics Limited (NASDAQ:KZIA) shares surged 88.6% to $1.26. Kazia Therapeutics, on Wednesday, announced result